Can new routes of administration have a place in the application of immunotherapy?
Immunotherapy typically requires intravenous administration, but this may not be the optimal or preferred route for all patients
New therapies, new toxicities
Side-effects may occur at unpredictable timepoints during a patient’s treatment journey and even after treatment cessation
Neoadjuvant or adjuvant immunotherapy – which is the best approach?
The role of neoadjuvant versus adjuvant immunotherapy is no simple comparison but instead involves a complex interplay of factors, based on tumour immune responsiveness, immunotherapy type, combination partners and trial design
Adjuvant immunotherapy does not improve disease-free survival in renal cell carcinoma
IMmotion010, CheckMate 914 and PROSPER miss their primary endpoints: back to square one for adjuvant immunotherapy?
Liquid biopsy moving to early cancer detection: is it still early times?
Despite the promises shown by some innovative technologies in the studies presented, they will not replace existing diagnostic modalities soon
New FGFR inhibitors show potential for the treatment of cholangiocarcinoma
Two early studies investigate the anticancer activity of derazantinib and RLY-4008 in patients with FGFR inhibitor-naïve cholangiocarcinoma
Has TIL therapy the potential to change cancer treatment?
After TILs have shown benefits in advanced melanoma, many ‘synthetic biology’ strategies can be conceived to potentially extend this clinical signal to other patient groups
TILs confirm to prolong PFS compared with immunotherapy in advanced melanoma
In a head-to-head comparison to the standard of care, tumour-infiltrating lymphocytes show clinical efficacy even in patients who are refractory to anti-PD-1 treatment
Next-generation sequencing can identify molecular alterations in glioma: are we ready for targeted treatments?
Three studies support the use of NGS to better understand the molecular drivers of this brain tumour, but effective targeted treatments are still lacking
Durvalumab plus cisplatin/gemcitabine is now standard of care for patients with advanced/metastatic biliary tract cancer
Updated overall survival data from TOPAZ-1 confirm clinically meaningful benefit of adding durvalumab to cisplatin/gemcitabine